DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Avapritinib
Avapritinib
NCCN Guidelines for Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes V.2.2021 –Interim on 07/21/20
Leukemia Insights June 2021
CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
PIONEER: a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent Or Smoldering Sy
Leukemia Insights Newsletter September 2019 MPN
GIST): Efficacy and Safety Data from Phase 3 VOYAGER Study 3461883 Yoon-Koo Kang1, Suzanne George2, Robin L
AYVAKIT (Avapritinib) RATIONALE for INCLUSION in PA PROGRAM
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
Inhibitory Effects of Midostaurin and Avapritinib on Myeloid Progenitors Derived from Patients with KIT D816V Positive Advanced Systemic Mastocytosis
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17–Mutant KIT Beth Apsel Winger1, Wilian A
Revolutions in Treatment Options in Gastrointestinal Stromal Tumours (Gists): the Latest Updates Revolutions in Treatment Options in GIST
Multi-Discipline Review
Oncology Approvals in 2020: a Year of Firsts in the Midst of a Pandemic
Oncology Oral, Other Therapeutic Class Review
AYVAKYT, Avapritinib
Prescribing Information
Study Protocol
CHMP Agenda of the 20-23 July 2020 Meeting
Top View
Using the Structural Kinome to Systematize Kinase Drug Discovery
Antiproliferative and Carbonic Anhydrase II Inhibitory
Clinical Response to Avapritinib by RECIST and Choi Criteria in ≥ 4Th
MHDL Update Additions Change in Prior-Authorization Status
Therapeutic Advances in Oncology
AVAPRITINIB (BLU-285) Mpfs 3.7 Mo ORR 20.0% Tkis Currently Approved for Metastatic GIST Disease
Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
Specialty Pipeline MONTHLY UPDATE
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Ayvakit® (Avapritinib) (Oral) Document Number: IC-0523 Last Review Date: 07/01/2020 Date of Origin: 02/04/2020 Dates Reviewed: 02/2020, 07/2020
CY 2020 CDER New Molecular Entity (NME) Drug & Original BLA Calendar Year Approvals As of Decemeber 31, 2020
In Gastrointestinal Stromal Tumors
Assessment of Vitamin D Levels in Newly Diagnosed Breast Cancer
Specialty Pipeline MONTHLY UPDATE
2021 Complex General Surgical Oncology: Key References
Oncology Agents Policy #: Rx.01.67
Summary of Risk Management Plan for AYVAKYT (Avapritinib)
Avapritinib CTOS 2018
Mutational Landscape in Myeloproliferative Neoplasms (MPN) and Eosinophilia: Diagnostic and Treatment – Section 12
Assessment Report
List Item Applications for New Human
Avapritinib 03/20
Tyrosine Kinase Inhibitors - Oral
An Oncology Mouthful: Updates and Pearls for Oral Oncolytics
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
Pipeline Report Report
Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
Prior Authorization — Premium
Policy Drug(S)
Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-Derived Xenograft Models Of
Prior Authorization Oncology – Sprycel® (Dasatinib Tablets)
Risk Assessment and Risk Mitigation Review(S)
Gastrointestinal Stromal Tumors (Gists): Novel Therapeutic Strategies with Immunotherapy and Small Molecules
Avapritinib: Preclinical Studies of a Promising Novel Therapeutic Option for Gastrointestinal Stromal Tumors
Download Overview
Labeling Tablets: 25 Mg, 50 Mg, 100 Mg, 200 Mg and 300 Mg
Increased Detection of KIT D816V Mutation in Peripheral Blood
Avapritinib in Unresectable Or Metastatic PDGFRA D842V-Mutant Gastrointestinal Stromal Tumours: Long- Term Efficacy and Safety Data from the NAVIGATOR Phase I Trial
Specialty Pipeline MONTHLY UPDATE
409 Oncology Drugs
Precision Oncology Drug Approvals in 2020 - New Drugs and Expanded Indications
Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
2020 Annual Report
Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
Publication Agenda CHMP 07-10 December 2020
Prior Authorization Criteria
Update on Molecular Genetics of Gastrointestinal Stromal Tumors
Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors
Tropomyosin Receptor Kinase Inhibitors in the Management Of
Human Medicines Highlights Newsletter’ and Then Click on ‘Subscribe to This Feed’
A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity
Tyrosine Kinase Receptors in Oncology
Interim Analysis of Avapritinib in Patients with Advanced Systemic Mastocytosis (Advsm)